AG001NNP

155141-29-0 | (2Z)-but-2-enedioic acid; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione

AG001NNP

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	155141-29-0
Catalog Number	AG001NNP(AGN-PC-0Q6TTQ)
Chemical Name	(2Z)-but-2-enedioic acid; 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
IUPAC Name	(Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
InChI	InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
InChI Key	SUFUKZSWUHZXAV-BTJKTKAUSA-N
MDL Number	MFCD03427306
Molecular Formula	C22H23N3O7S
Molecular Weight	473.4989
NSC Number	717764
SMILES	C(=C\C(O)=O)\C(O)=O.C(C1SC(=O)NC1=O)C2=CC=C(OCCN(C)C3=CC=CC=N3)C=C2
Synonyms	5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, Avandia, BRL 49653, BRL-49653, BRL49653, rosiglitazone, rosiglitazone maleate, Rosiglitazone maleate, 155141-29-0, Avandia, Rosiglitazone (maleate), Rosiglitazone Maleate [USAN], BRL 49653-C, BRL 49653C, BRL-49653C, Avandamet, BRL-49653-C, (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1), Nyracta, Rosiglitazone XR, 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleate, 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1), Venvia, CHEBI:8892, (Z)-but-2-enedioic acid; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, SMR000471612, Avandia (TN), SB-206846, SB-210232, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, Rosiglitazone maleate (JAN/USAN), 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), C18H19N3O3S.C4H4O4, Rosiglitazone-maleate, AC1NQXYB, 5-{P-[2-(METHYL-2-PYRIDYLAMINO)ETHOXY]BENZYL}-2,4-THIAZOLIDINEDIONE MALEATE, (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; but-2-enedioic acid, maleic acid; rosiglitazone, DSSTox_CID_3569, CHEMBL843, DSSTox_RID_77086, DSSTox_GSID_23569, SCHEMBL19023, MLS001306472, MLS001401426, DTXSID2023569, SUFUKZSWUHZXAV-BTJKTKAUSA-N, HMS2051B11, HMS2233I10, Tox21_302367, AC-737, MFCD03427306, NSC717764, s2505, AKOS015961534, Avandia administration for 6-12 weeks, CCG-100943, CCG-208126, CS-1692, KS-5027, NC00193, NSC-717764, NCGC00255233-01, 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate, 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate, AN-15585, BC207045, CPD000471612, HY-14600, SAM001246610, AB0073096, LS-173475, CAS-155141-29-0, SW197573-4, D00596, K-4902, Z-8295, 141R290, A809615, 2, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione maleate, 5-{4-[2-(Methylpyridin-2-ylamino)ethoxy]benzyl}thiazolidine-2,4-dione maleate, maleic acid; 5-[[4-[2-[methyl(2-pyridyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione, (+ -)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1), (Z)-2-butenedioic acid; 5-[[4-[2-[methyl(2-pyridinyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione, Avandaryl, rosiglitazone, Mixture Name, (Z)-but-2-enedioic acid, D0K5ER, UNII-KX2339DP44, Brl 49653, Brl-49653, KX2339DP44, Avandiaadministration for 6-12 weeks, ACN-048754, CID5281055, CS-O-02261, A4302, C18-H19-N3-O3-S.C4-H4-O4, 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1), 122320-73-4, 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(2Z)-2-butenedioate (1:1),

Complexity	588
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	2
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Exact Mass	473.126g/mol
Formal Charge	0
Heavy Atom Count	33
Hydrogen Bond Acceptor Count	10
Hydrogen Bond Donor Count	3
Isotope Atom Count	0
Molecular Weight	473.5g/mol
Monoisotopic Mass	473.126g/mol
Rotatable Bond Count	9
Topological Polar Surface Area	171A^2
Undefined Atom Stereocenter Count	1
Undefined Bond Stereocenter Count	0

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number